Wendy Diller

Senior Writer/Market Analyst

20 Years of Experience

About

Wendy writes on the medical devices and clinical diagnostics sectors, where she focuses on orthopedics/spine, molecular diagnostics and personalized medicine, clinical genomics, womens’ health/ femtech, and reimbursement/commercial strategy and innovation related to these specialties. She welcomes and encourages ideas and input from members of the MedTech Strategist Community.

Her career spans more than 20+ years as a top writer and manager focused on qualitative analysis of the global life sciences industry. She is Chair of Young Women in Bio Metro NY, an organization devoted to encouraging secondary students in the NY area to pursuit STEM careers and on the board of the Columbia Business School of Alumni Club NY

Specialties
Publications
Articles from Wendy Diller:
Read all from this author
Investors & Dealmaking

Record Series A's, Robust Late-Stage Deals in H1 2026, But Are There Exits?

  • 2026-08-19 00:00:00.0
  • Wendy Diller
  • MedTech Strategist

The first half of 2026 saw record first financing activity in medtech, including nine $20 million-plus deals, and robust late-stage deals of $50 million or more, according to a mid-year 2026 HSBC Venture Healthcare Report, but concerns about exits and lagging interest in some indications linger. Jon Norris, managing director at HSBC, and lead author, discusses recent medtech trends with MTS' Wendy Diller in a two-part video interview.

Read Article